Brought to you by 
Ilex and Lilly collaborate on oncology compound
14 Feb 2000
Executive Summary
Ilex Oncology (cancer therapeutics) and Lilly will collaborate to develop Lilly compound, LY295501 (diarysulfonylurea), which in Phase I clinical trials has shown promise as an antitumor agent relative to lung, ovarian, pancreatic, and colon cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ilex and Lilly collaborate on oncology compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice